MICHELLE HANCOCK: Open Payments
NPI 1386355774 · URBANDALE, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,157 in 129 payments from 19 companies in 2025. Trend: 2023 $845 · 2024 $1,896 · 2025 $2,157
Food & beverage: $2,150Education: $8
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 27 | $401 |
| Otsuka America Pharmaceutical, Inc. | 17 | $286 |
| Teva Pharmaceuticals USA, Inc. | 11 | $231 |
| MDD US Operations, LLC | 17 | $177 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $175 |
| E.R. Squibb & Sons, L.L.C. | 7 | $166 |
| Lundbeck LLC | 7 | $146 |
| Vanda Pharmaceuticals Inc. | 6 | $138 |
| Janssen Pharmaceuticals, Inc | 4 | $74 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $66 |
Products named: VRAYLAR, REXULTI, Qelbree, CAPLYTA, COBENFY, AUSTEDO XR, FANAPT, UZEDY.
Industry payments across IA — which companies pay providers there.
